Comparison of Low Fixed Dose Versus Standard-Dose Rituximab to Treat Thrombotic Thrombocytopenic Purpura in the Acute Phase and Preemptively During Remission

The standard dose of rituximab used in B-cell hematological malignancies, 375  mg/m2 weekly, may be excessive for autoimmune conditions. Successful use of a low, fixed dose of 100-200 mg of rituximab, weekly for 4 weeks, has been reported in the literature in the treatment of autoimmune thrombotic thrombocytopenic purpura (aTTP). We retrospectively analyzed our rituximab data in aTTP over a 13-year-period for 39 patients, with the aim of comparing response and outcomes with a standard lymphoma-dose course versus a low fixed 100 mg-dose course.
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research